TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22362859

Group type: EXPERIMENTAL
Intervention: Vilanterol trifenatate (VI) 12.5-50 μg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vilanterol trifenatate (VI) 3, 6.25, 12.5, 25 and 50 μg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vilanterol trifenatate (VI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15825065

Group type: EXPERIMENTAL
Intervention: Trichuris suis ova (2500 ova orally at 2-week intervals for 12 weeks)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo (oral administration at 2-week intervals for 12 weeks)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Trichuris suis ova
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Trichuris suis ova and Placebo
Number of subjects: 54
Study: 12614246

Group type: EXPERIMENTAL
Intervention: LHRH agonist monotherapy (group 1)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: LHRH agonist and chlormadinone acetate (group 2)
Number of subjects: 151
Study: 10229436

Group type: EXPERIMENTAL
Intervention: SASSS method for the spine
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: BASRI
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: New York method for SI joints
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Larsen hip scores
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Overall assessment of change
Number of subjects: 187
Study: 8657212

Group type: EXPERIMENTAL
Intervention: Endometrial resection
Number of subjects: 525
Study: 1809525

Group type: EXPERIMENTAL
Intervention: 5% vitamin E gel
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 48

Group type: COMPARATOR
Intervention: 0.12% chlorhexidine gluconate
Number of subjects: 48
Study: 6605713

Group type: EXPERIMENTAL
Intervention: Cefadroxil, 500 mg twice daily
Number of subjects: 34

Group type: COMPARATOR
Intervention: Cephalexin, 250 mg four times daily
Number of subjects: 34
Study: 31566281

Group type: EXPERIMENTAL
Intervention: Sound media (listening to music)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Visual media (watching videos)
Number of subjects: 95

Group type: COMPARATOR
Intervention: No media distraction (control group)
Number of subjects: 95
Study: 27623757

Group type: EXPERIMENTAL
Intervention: L-arginine (6 g)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 28595861

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 1246

Group type: COMPARATOR
Intervention: Percutaneous coronary intervention (PCI) with drug-eluting stents
Number of subjects: 1246
Study: 26983039

Group type: EXPERIMENTAL
Intervention: Combination therapy with Tamsulosin plus Finasteride
Number of subjects: 92

Group type: COMPARATOR
Intervention: Monotherapy with Tamsulosin
Number of subjects: 92
Study: 23972722

Group type: EXPERIMENTAL
Intervention: 70 Gy salvage radiation therapy (RT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: 3D-CRT
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Dummy run (DR) treatment plan for 70 Gy
Number of subjects: 30
Study: 21122628

Group type: EXPERIMENTAL
Intervention: Phytochemical-enhanced diet (PED)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Modified Mediterranean-style, low-glycemic-load diet (MED)
Number of subjects: 24
Study: 18066684

Group type: COMPARATOR
Intervention: Low-frequency rTMS (110% motor threshold, 1 Hz, 2000 stimuli/day)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: High-frequency priming stimulation (6 Hz, 90% motor threshold, 960 stimuli) followed by low-frequency rTMS (110% motor threshold, 1 Hz, 1040 stimuli/day)
Number of subjects: 32
Study: 16644619

Group type: EXPERIMENTAL
Intervention: Ester-C (1000 mg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Ascorbic Acid (AA) (1000 mg)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Ester-C
Number of subjects: 50

Group type: COMPARATOR
Intervention: Ascorbic Acid (AA)
Number of subjects: 50
Study: 12803598

Group type: EXPERIMENTAL
Intervention: Fentanyl 2 microg kg‐1 intravenously
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group receiving equal volumes of normal saline
Number of subjects: 41
Study: 10662706

Group type: EXPERIMENTAL
Intervention: TPNGLN (0.4 g x kg(‐1) x day(‐1))
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: TPNGLN+GH/IGF-I (0.2 IU. kg(‐1). day(‐1) GH and 160 microg x kg(‐1) x day(‐1) IGF-I)
Number of subjects: 17

Group type: COMPARATOR
Intervention: TPN
Number of subjects: 17
Study: 8646806

Group type: EXPERIMENTAL
Intervention: 5-FU + FA (group A)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: 5-FU + FA + MTX (group B)
Number of subjects: 88
Study: 2001826

Group type: EXPERIMENTAL
Intervention: 300 mg ranitidine at night
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 40 mg omeprazole every morning
Number of subjects: 22
Study: 6354100

Group type: EXPERIMENTAL
Intervention: AF (ADM, 40 mg/m2 q. 3W plus 5‐FUDS, 4 mg/kg daily)
Number of subjects: 119

Group type: COMPARATOR
Intervention: MF (MMC, 10 mg/m2 q. 3W plus 5‐FUDS, 4 mg/kg daily)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: AF
Number of subjects: 119

Group type: COMPARATOR
Intervention: MF
Number of subjects: 119
Study: 30508988

Group type: EXPERIMENTAL
Intervention: Active treatment (RF lesions performed)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham treatment (no RF lesions performed)
Number of subjects: 30
Study: 28390208

Group type: EXPERIMENTAL
Intervention: Waterpik® Water Flosser (WF) plus manual toothbrush
Number of subjects: 28

Group type: COMPARATOR
Intervention: Interdental brushes (IDBs) plus manual toothbrush
Number of subjects: 28
Study: 24697580

Group type: EXPERIMENTAL
Intervention: High IL-6-sR (≥ 37,401.36 pg/mL, highest tertile) at Year 16
Number of subjects: 905

Group type: EXPERIMENTAL
Intervention: High IL-6-sR at both time points
Number of subjects: 905

Group type: EXPERIMENTAL
Intervention: Transitioned to a high level of IL-6-sR
Number of subjects: 905
Study: 22240336

Group type: EXPERIMENTAL
Intervention: Endovenous laser ablation (EVLA)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Ultrasound-guided foam sclerotherapy (UGFS)
Number of subjects: 66
Study: 20575721

Group type: EXPERIMENTAL
Intervention: Telephone-based referral-care management (TBR-CM) intervention with brief motivational telephone sessions
Number of subjects: 169

Group type: COMPARATOR
Intervention: Usual care consisting of psychiatric appointment and standard institutional reminders
Number of subjects: 169
Study: 18223031

Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 3849

Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 3849

Group type: COMPARATOR
Intervention: Glyburide
Number of subjects: 3849

Group type: COMPARATOR
Intervention: Rosiglitazone vs Metformin
Number of subjects: 3849

Group type: COMPARATOR
Intervention: Rosiglitazone vs Glyburide
Number of subjects: 3849
Study: 16009165

Group type: EXPERIMENTAL
Intervention: Cetrorelix acetate (3 mg SC)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Ganirelix acetate (0.25 mg SC daily)
Number of subjects: 185
Study: 12225274

Group type: EXPERIMENTAL
Intervention: Quantitative information in advertisements
Number of subjects: 1504

Group type: EXPERIMENTAL
Intervention: Compelling evidence for claims
Number of subjects: 1504

Group type: EXPERIMENTAL
Intervention: Explicitly reporting quantitative outcomes
Number of subjects: 1504
Study: 9990629

Group type: EXPERIMENTAL
Intervention: Predischarge ICD defibrillation test
Number of subjects: 31

Group type: COMPARATOR
Intervention: No predischarge ICD defibrillation test
Number of subjects: 31
Study: 7781432

Group type: EXPERIMENTAL
Intervention: Extracorporeal piezoelectric lithotripsy (EPL)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Intracorporeal electrohydraulic lithotripsy (EHL)
Number of subjects: 35
Study: 2138749

Group type: EXPERIMENTAL
Intervention: slow-release carbamazepine
Number of subjects: 114

Group type: COMPARATOR
Intervention: carbamazepine
Number of subjects: 114
Study: 555598

Group type: EXPERIMENTAL
Intervention: Theolair SR (10 mg/kg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Theo-Dur (10 mg/kg)
Number of subjects: 8
Study: 30653957

Group type: EXPERIMENTAL
Intervention: Netarsudil 0.02% once a day (q.d.)
Number of subjects: 756

Group type: EXPERIMENTAL
Intervention: Netarsudil 0.02% twice a day (b.i.d.)
Number of subjects: 756

Group type: COMPARATOR
Intervention: Timolol 0.5% twice a day (b.i.d.)
Number of subjects: 756
Study: 28732822

Group type: EXPERIMENTAL
Intervention: Atypical coverage at admission
Number of subjects: 179

Group type: COMPARATOR
Intervention: Beta-lactam monotherapy continued
Number of subjects: 179
Study: 26410680

Group type: EXPERIMENTAL
Intervention: Early intubation (within 12 hours)
Number of subjects: 776

Group type: EXPERIMENTAL
Intervention: Delayed intubation
Number of subjects: 776

Group type: COMPARATOR
Intervention: Never intubated
Number of subjects: 776

Group type: COMPARATOR
Intervention: ICUs with lowest frequency of early intubation
Number of subjects: 776
Study: 23403074

Group type: EXPERIMENTAL
Intervention: Teams Talking Trials (TTT) Workshop
Number of subjects: 22
Study: 20627440

Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Number of subjects: 218

Group type: COMPARATOR
Intervention: Prescriptive advice
Number of subjects: 218
Study: 18616391

Group type: EXPERIMENTAL
Intervention: Field experiments
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomized experiments
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regression discontinuity designs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Short interrupted time series
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonrandomized experiments
Number of subjects: 0
Study: 17522328

Group type: EXPERIMENTAL
Intervention: Tuberculosis antigens delivered by adenylate cyclase
Number of subjects: 119

Group type: COMPARATOR
Intervention: Native tuberculosis antigens (without adenylate cyclase delivery)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Gamma interferon responses to tuberculosis antigens (with or without delivery by adenylate cyclase)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Ex vivo responses to tuberculosis antigens delivered by adenylate cyclase
Number of subjects: 119
Study: 15172406

Group type: EXPERIMENTAL
Intervention: Light-to-moderate alcohol intake (1 to 10 drinks/week)
Number of subjects: 2231

Group type: EXPERIMENTAL
Intervention: Heavy alcohol intake (>10 drinks/week)
Number of subjects: 2231

Group type: EXPERIMENTAL
Intervention: Alcohol consumption reported three months after MI
Number of subjects: 2231
Study: 11840581

Group type: EXPERIMENTAL
Intervention: Edrophonium 1 mg/kg and atropine 0.01 mg/kg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 9806672

Group type: EXPERIMENTAL
Intervention: Propofol anesthesia
Number of subjects: 20

Group type: COMPARATOR
Intervention: Isoflurane anesthesia
Number of subjects: 20
Study: 7625120

Group type: EXPERIMENTAL
Intervention: 160 RIA antigen unit dose
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: All dosage groups
Number of subjects: 195
Study: 1978161

Group type: EXPERIMENTAL
Intervention: daily injections of growth hormone (rhGH) at 30 IU/m2 per week
Number of subjects: 41

Group type: COMPARATOR
Intervention: no treatment
Number of subjects: 41
Study: 321723

Group type: EXPERIMENTAL
Intervention: Human chorionic gonadotrophin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both agents
Number of subjects: 0
Study: 31995239

Group type: EXPERIMENTAL
Intervention: 100% of estimated energy needs
Number of subjects: 35

Group type: COMPARATOR
Intervention: 40% of estimated energy needs
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Real-time energy flow rate (high tertile)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Real-time energy flow rate (middle tertile)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Upper median of real-time energy flow rate
Number of subjects: 35
Study: 30137394

Group type: EXPERIMENTAL
Intervention: Exposure to social adverse childhood experiences (ACEs)
Number of subjects: 2120

Group type: EXPERIMENTAL
Intervention: Exposure to community violence (for women)
Number of subjects: 2120

Group type: EXPERIMENTAL
Intervention: Exposure to peer violence (for men)
Number of subjects: 2120
Study: 27678453

Group type: EXPERIMENTAL
Intervention: ALPHA + CTCs
Number of subjects: 0

Group type: COMPARATOR
Intervention: ALPHA
Number of subjects: 0
Study: 26410565

Group type: EXPERIMENTAL
Intervention: Rhinochill
Number of subjects: 70

Group type: COMPARATOR
Intervention: Blanketrol
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 70
Study: 23507549

Group type: EXPERIMENTAL
Intervention: Prophylactic oxytocin (10, 40, or 80 U)
Number of subjects: 1798

Group type: EXPERIMENTAL
Intervention: Amnioinfusion
Number of subjects: 1798

Group type: EXPERIMENTAL
Intervention: Hispanic ethnicity
Number of subjects: 1798

Group type: EXPERIMENTAL
Intervention: Non-Hispanic white ethnicity
Number of subjects: 1798

Group type: EXPERIMENTAL
Intervention: Preeclampsia
Number of subjects: 1798

Group type: EXPERIMENTAL
Intervention: Chorioamnionitis
Number of subjects: 1798
Study: 21709202

Group type: EXPERIMENTAL
Intervention: ASA404 (vadimezan) 1800 mg/m2, given intravenously once every 3 weeks for six cycles followed by maintenance ASA404
Number of subjects: 1299

Group type: COMPARATOR
Intervention: Placebo, given intravenously once every 3 weeks for six cycles followed by maintenance placebo
Number of subjects: 1299

Group type: EXPERIMENTAL
Intervention: ASA404 (vadimezan) 1800 mg/m2
Number of subjects: 1299

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1299
Study: 19545579

Group type: EXPERIMENTAL
Intervention: Game of Dice Task (GDT)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Iowa Gambling Task (IGT)
Number of subjects: 44
Study: 16181713

Group type: EXPERIMENTAL
Intervention: Seated lateral-reaching tasks
Number of subjects: 38
Study: 12527976

Group type: COMPARATOR
Intervention: 0 g glucose (PLAC)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 25 g glucose (LOW)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 75 g glucose (MED)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 200 g glucose (HIGH)
Number of subjects: 9
Study: 10583700

Group type: EXPERIMENTAL
Intervention: Haloperidol 30 mg/day plus Piracetam 3200 mg/day
Number of subjects: 30

Group type: COMPARATOR
Intervention: Haloperidol 30 mg/day plus Placebo
Number of subjects: 30
Study: 8916658

Group type: EXPERIMENTAL
Intervention: Probucol
Number of subjects: 54

Group type: COMPARATOR
Intervention: Pravastatin
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 54
Study: 1988321

Group type: EXPERIMENTAL
Intervention: Ginger (1 g daily for 4 days)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (lactose, q.i.d. for 4 days)
Number of subjects: 30
Study: 6874891

Group type: EXPERIMENTAL
Intervention: Dexamethasone phosphate (5 mg each) at 12-h intervals for 4 injections
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Dexamethasone phosphate
Number of subjects: 74
Study: 3890241

Group type: EXPERIMENTAL
Intervention: Preoperative percutaneous transhepatic biliary drainage (PTBD) for 13.8 +/- 5.8 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Immediate surgery
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Preoperative percutaneous transhepatic biliary drainage (PTBD)
Number of subjects: 30
Study: 31563133

Group type: EXPERIMENTAL
Intervention: High Flow Nasal Cannula (HFNC)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Nasal Continuous Positive Airway Pressure (nCPAP)
Number of subjects: 107
Study: 31758633

Group type: EXPERIMENTAL
Intervention: Head CT Choice decision aid
Number of subjects: 971

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 971
Study: 28669789

Group type: EXPERIMENTAL
Intervention: Self-directed interactive video-based instruction (IVBI)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Instructor-led teaching
Number of subjects: 50
Study: 26657041

Group type: EXPERIMENTAL
Intervention: e‐Learning + Workshop (e‐L + W)
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: e‐Learning (e‐L)
Number of subjects: 322

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 322
Study: 24937205

Group type: COMPARATOR
Intervention: ALA
Number of subjects: 8

Group type: COMPARATOR
Intervention: PRO
Number of subjects: 8
Study: 22747865

Group type: EXPERIMENTAL
Intervention: Ureteroscopic pneumatic lithotripsy (URS)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Extracorporeal shock wave lithotripsy (ESWL)
Number of subjects: 136
Study: 20060288

Group type: EXPERIMENTAL
Intervention: Cisplatin and capecitabine (CX)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Epirubicin, cisplatin and capecitabine (ECX)
Number of subjects: 91
Study: 18257186

Group type: EXPERIMENTAL
Intervention: Cauterization with electric pyropuncture needle (n=84)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Incision (n=24)
Number of subjects: 108
Study: 15929678

Group type: EXPERIMENTAL
Intervention: Exenatide 2.5 microg b.i.d.
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Exenatide 5.0 microg b.i.d.
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Exenatide 7.5 microg b.i.d.
Number of subjects: 156
Study: 12789024

Group type: EXPERIMENTAL
Intervention: Suprapubic catheter
Number of subjects: 165

Group type: COMPARATOR
Intervention: Transurethral catheter
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Suprapubic catheter (excluding those who underwent recatheterization)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Patient satisfaction
Number of subjects: 165
Study: 10591680

Group type: EXPERIMENTAL
Intervention: Raloxifene hydrochloride 60 mg/d
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Raloxifene hydrochloride 150 mg/d
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens (CEEs) 0.625 mg/d
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 8734305

Group type: EXPERIMENTAL
Intervention: Meal with 28% lipids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Meal with 58% lipids
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both meals
Number of subjects: 0
Study: 1661506

Group type: EXPERIMENTAL
Intervention: Cavinton (additional to conventional therapy)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 61
Study: 6818707

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate 2 mg/ml
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate 10 mg/ml
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate 20 mg/ml
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate 40 mg/ml
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 10
Study: 31081350

Group type: EXPERIMENTAL
Intervention: Preplanned changing criterion designs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Response-guided changing criterion designs
Number of subjects: 0
Study: 29925724

Group type: EXPERIMENTAL
Intervention: Thoracic epidural anesthesia (TEA)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Intercostal nerve block (INB)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Paravertebral nerve block (PVB)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 300
Study: 27732083

Group type: EXPERIMENTAL
Intervention: Individualized acupuncture treatment (AT)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 76
Study: 25055057

Group type: EXPERIMENTAL
Intervention: Fresh rose flowers as an olfactory stimulant
Number of subjects: 19

Group type: COMPARATOR
Intervention: Air as a control
Number of subjects: 19
Study: 22430237

Group type: EXPERIMENTAL
Intervention: Recombinant tissue plasminogen activator (n=78)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (n=22)
Number of subjects: 100
Study: 18635681

Group type: EXPERIMENTAL
Intervention: Early discharge programme (EDP)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Standard discharge programme (SDP)
Number of subjects: 140
Study: 17605894

Group type: EXPERIMENTAL
Intervention: NXY-059
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 15784786

Group type: EXPERIMENTAL
Intervention: Behavioral intervention focusing on stressors leading to exhaustion and support for recovery
Number of subjects: 710

Group type: COMPARATOR
Intervention: Usual-care group
Number of subjects: 710

Group type: EXPERIMENTAL
Intervention: Behavioral intervention
Number of subjects: 710
Study: 11932877

Group type: EXPERIMENTAL
Intervention: Joint protection and home hand exercises (JPE group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (information session about hand OA)
Number of subjects: 40
Study: 10325836

Group type: EXPERIMENTAL
Intervention: PCA with piritramide 0.75 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: PCA with piritramide 1.5 mg
Number of subjects: 60
Study: 8938545

Group type: EXPERIMENTAL
Intervention: Activated hepatic stellate cells (alpha-SMA+ve) in alcoholic patients
Number of subjects: 38

Group type: COMPARATOR
Intervention: Activated hepatic stellate cells (alpha-SMA+ve) in control biopsies
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Correlation of hepatic stellate cells activation with steatosis grade 0
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Correlation of hepatic stellate cells activation with steatosis grade 1
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Correlation of hepatic stellate cells activation with steatosis grade 2
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Correlation of hepatic stellate cells activation with steatosis grade 3
Number of subjects: 38
Study: 1679316

Group type: EXPERIMENTAL
Intervention: Nizatidine 300 mg daily
Number of subjects: 43

Group type: COMPARATOR
Intervention: Cimetidine 800 mg daily
Number of subjects: 43
Study: 6848648

Group type: EXPERIMENTAL
Intervention: Alcohol (1.1 ml/kg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 11777833

Group type: EXPERIMENTAL
Intervention: Recombinant glycoprotein (RGP) vaccines
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 29858875

Group type: EXPERIMENTAL
Intervention: L-PRF membranes
Number of subjects: 8

Group type: COMPARATOR
Intervention: Free gingival graft (FGG)
Number of subjects: 8
Study: 26775293

Group type: EXPERIMENTAL
Intervention: Agomelatine (25mg/d)
Number of subjects: 27
Study: 24939364

Group type: EXPERIMENTAL
Intervention: Arthroscopy after locked plating of proximal humeral fractures
Number of subjects: 45